Amylyx Pharmaceuticals, Inc.
AMLX
Rankning i aktier
#4500
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aktiekurs
$27.25
Marknadsvärde
$3.42B
Förändring (1 dag)
3.45%
Förändring (1 år)
82.27%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
EPS för Amylyx Pharmaceuticals, Inc. (AMLX)
EPS per June 2026 TTM: $-1.41
Enligt Amylyx Pharmaceuticals, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-1.41. Vid slutet av 2023 hade bolaget ett EPS på $0.73, en ökning jämfört med EPS från 2022 som var $-2.98.
EPS-historik för Amylyx Pharmaceuticals, Inc. från 2019 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
